Follow
Sheena Smith
Sheena Smith
Head of Program Management, Vector BioPharma
Verified email at vectorbiopharma.com
Title
Cited by
Cited by
Year
Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains
DT Harris, MV Hager, SN Smith, Q Cai, JD Stone, P Kruger, M Lever, ...
The Journal of Immunology 200 (3), 1088-1100, 2018
1592018
Yeast lipin 1 orthologue pah1p regulates vacuole homeostasis and membrane fusion
T Sasser, QS Qiu, S Karunakaran, M Padolina, A Reyes, B Flood, S Smith, ...
Journal of Biological Chemistry 287 (3), 2221-2236, 2012
1112012
Changing the peptide specificity of a human T-cell receptor by directed evolution
SN Smith, Y Wang, JL Baylon, NK Singh, BM Baker, E Tajkhorshid, ...
Nature communications 5 (1), 5223, 2014
452014
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
N Kirchhammer, MP Trefny, M Natoli, D Brücher, SN Smith, F Werner, ...
Science translational medicine 14 (653), eabm9043, 2022
392022
Residual feed intake of Angus beef cattle divergently selected for feed conversion ratio
SN Smith, ME Davis, SC Loerch
Livestock Science 132 (1-3), 41-47, 2010
362010
T cell receptor engineering and analysis using the yeast display platform
SN Smith, DT Harris, DM Kranz
Yeast Surface Display: Methods, Protocols, and Applications, 95-141, 2015
332015
An engineered switch in T cell receptor specificity leads to an unusual but functional binding geometry
DT Harris, NK Singh, Q Cai, SN Smith, CW Vander Kooi, E Procko, ...
Structure 24 (7), 1142-1154, 2016
292016
Engineering t cell receptors
SN Smith, DM Kranz
US Patent App. 14/417,434, 2015
272015
iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy
D Brücher, N Kirchhammer, SN Smith, J Schumacher, N Schumacher, ...
Molecular Therapy-Methods & Clinical Development 20, 572-586, 2021
262021
The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody
SN Smith, R Schubert, B Simic, D Brücher, M Schmid, N Kirk, PC Freitag, ...
Proceedings of the National Academy of Sciences 118 (21), e2017925118, 2021
212021
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide–HLA-A2 complexes
SN Smith, D Sommermeyer, KH Piepenbrink, SJ Blevins, H Bernhard, ...
Journal of molecular biology 425 (22), 4496-4507, 2013
192013
Engineered high-affinity human t cell receptors
SN Smith, DT Harris, DM Kranz, PD Greenberg, TM Schmitt
US Patent 10,344,075, 2019
92019
Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness
D Brücher, V Franc, SN Smith, AJR Heck, A Plückthun
MAbs 12 (1), 1792084, 2020
82020
Engineered high-affinity human t cell receptors
SN Smith, DT Harris, DM Kranz
US Patent 10,023,625, 2018
72018
Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo
PC Freitag, M Kaulfuss, L Flühler, J Mietz, F Weiss, D Brücher, J Kolibius, ...
Molecular Therapy-Methods & Clinical Development 29, 120-132, 2023
62023
CRISPR-clear imaging of melanin-rich B16-derived solid tumors
R Schubert, T Bae, B Simic, SN Smith, SH Park, G Nagy-Davidescu, ...
Communications Biology 6 (1), 370, 2023
22023
Successful IL-12 cancer immunotherapy requires NK cell-derived CCL5 for anti-tumor DC-T cell crosstalk
N Kirchhammer, MP Trefny, M Natoli
bioRxiv, 2021
22021
Engineering t cell receptors
SN Smith, DM Kranz
US Patent 11,384,133, 2022
12022
Engineered high-affinity human t cell receptors
SN Smith, DT Harris, DM Kranz
US Patent App. 17/586,652, 2022
2022
Adaptive anti-tumor immunity is orchestrated by a population of CCL5-producing tissue-resident NK cells
N Kirchhammer, MP Trefny, M Natoli, D Brücher, SN Smith, F Werner, ...
bioRxiv, 2021.05. 27.445981, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20